Clinical trials: Clinical Investigation in Memory Centers
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement and Clinical Utility PrecivityAD2(TM) Clinician Survey
There is a major unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP II (NCT06025877)
- Testing
- PrecivityAD2(TM) blood test
- Where
- 9 sites in United States
- Volunteers
- 400 people
- Sponsor
- C2N Diagnostics
Traumatic Brain Injury
Non-invasive Deep Brain Stimulation to Improve Spatial Navigation Abilities in Individuals Following Traumatic Brain Injury
Impairments in spatial memory and spatial navigation are commonly reported amongst patients presenting post-traumatic brain injury (TBI).
- Trial name
- NCT07271524
- Testing
- Transcranial electric stimulation
- Where
- 2 sites in Switzerland
- Volunteers
- 25 people
- Sponsor
- Friedhelm Hummel
Cognitive Impairment, Memory Complaint
Performance of AclarusDx® a Blood-Based Transcriptomic Test for AD, in French Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Cognitive Impairment, Memory Complaint, Clinical Investigation in Memory Centers
- Trial name
- DIALOG (NCT02221661)
- Volunteers
- 606 people
- Sponsor
- Diaxonhit
Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI
Auditory Stimulation During Sleep to Enhance Long-Term Memory in Amnestic MCI
This study aims to evaluate the efficacy and safety of Elevvo AudiStim, a sleep auditory stimulation device, as a symptomatic treatment for patients with amnestic mild cognitive impairment (aMCI).
- Conditions
- Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI, Alzheimer or Mild Cognitive Impairment
- Trial name
- NCT07402590
- Testing
- Auditory Stimulation
- Where
- Spain
- Volunteers
- 37 people
- Sponsor
- Bitbrain
Mild Cognitive Impairment, Neurocardiogenic Syncope
VINCI-AD: An Investigation of Transcutaneous Vagus Nerve Stimulation in Mild Cognitive Impairment.
The VINCI-AD study will investigate the impact of non-invasive vagus nerve stimulation (VNS) on memory in participants with existing mild memory impairment. VNS is a safe, existing treatment, licensed in epilepsy and depression.
- Conditions
- Mild Cognitive Impairment, Neurocardiogenic Syncope, Memory Impairment, Inflammatory Response
- Trial name
- NCT05514756
- Testing
- Active t-VNS, Baseline assessments
- Where
- Ireland
- Volunteers
- 40 people
- Sponsor
- Tallaght University Hospital
Alzheimer Disease, Memory Complaint
Investigation of AlzHeimer's Predictors in Subjective Memory Complainers - Extension Study
A regional, single-center, prospective, observational academic cohort will follow subjects who previously participated in the INSIGHT study and who agree an extension of their follow-up in the INSIGHT-2 research for additional…
- Conditions
- Alzheimer Disease, Memory Complaint, Memory Disorders
- Trial name
- INSIGHT-2 (NCT05806697)
- Testing
- Electroencephalogram (EEG), Oculomotor tests, MRI
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Memory Disorder, Retention Disorder, Cognitive
Investigation of Memantine in the Treatment of Memory, Concentration or Attention Problems
In this study, memantine will be tested in a new indication: in the treatment of subjective memory, concentration, or attention problems (subjective cognitive impairment) in the absence of dementia.
- Conditions
- Memory Disorder, Retention Disorder, Cognitive, Subjective Cognitive Impairment, Memory, Concentration or Attention Problems
- Trial name
- NCT01261741
- Testing
- Memantine
- Where
- 14 sites in Germany, United Kingdom
- Volunteers
- 299 people
- Sponsor
- Merz Pharmaceuticals GmbH
Alzheimer Disease
A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease.
- Trial name
- GREEN MEMORY (NCT04520412)
- Testing
- GV-971
- Where
- 171 sites in United States, Australia and 8 more
- Volunteers
- 2,046 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Neurologic Disorder, Subarachnoid Hemorrhage, Aneurysmal
Hippocampal Volume and Memory Functions in Aneurysmal Subarachnoid Hemorrhage
Neuropsychological and functional long-term consequences of subarachnoid hemorrhages (SAH) represent a great challenge, since sometimes considerable cognitive deficits occur without evidence of substantial brain damage.
- Trial name
- NCT04449666
- Testing
- Neuropsychological assessment and structural MRI
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- BDH-Klinik Hessisch Oldendorf
Dysentery, Bacillary
A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study
GVGH Shigella Sonnei 1970GAHB is a vaccine aimed at preventing the disease caused by Shigella sonnei. A post-hoc analysis of subjects who participated in the parent study showed significantly different responses in subjects with…
- Trial name
- NCT03089879
- Testing
- GVGH Shigella sonnei 1790GAHB vaccine
- Where
- France
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cognitive Impairment, Mild, Cognitive Dysfunction
MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment
This is a randomized, double-blind, placebo-controlled, parallel group study. The use of placebo is appropriate to minimize bias related to treatment expectations of the subject, study partner, and site investigator, as well as…
- Conditions
- Cognitive Impairment, Mild, Cognitive Dysfunction, Amyloid Plaque, Neurodegenerative Disease, Hereditary
- Trial name
- NCT06177028
- Testing
- Lenalidomide 10 mg
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Alzheimer's Disease, Parkinson's Disease
Evaluation of a Diet in Patients With Senile Dementia
The most common symptoms associated to senile dementia disease are confusion about schedules, hyperactivity... In this sense, these patients have frequently poor nutrition, resulting in malnutrition problems or malnutrition high…
- Conditions
- Alzheimer's Disease, Parkinson's Disease, Senile Dementia
- Trial name
- SUPRESSI (NCT01192529)
- Testing
- Supressi. T-Diet plus Range, High Protein. T-Diet plus Range
- Where
- 3 sites in Spain
- Volunteers
- 184 people
- Sponsor
- Vegenat, S.A.
Neurodegenerative Diseases, Memory Disturbances
Health Technology Assessment of Diagnostic Approaches in Alzheimer's Disease
Background: New research criteria for the diagnosis of Alzheimer's disease (AD) have recently been developed to enable an early diagnosis of AD pathophysiology by relying on emerging biomarkers.
- Trial name
- NCT01450891
- Where
- 4 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- Maastricht University Medical Center
Traumatic Brain Injury
Plasticity of Deep Brain Structures in Mild Cognitive Impairment and Healthy Aging
Acute and chronic cognitive impairment (TBI and MCI) is one of the most common problems in the growing and aging society of the 21st century. At an individual level, not all brain structures are affected with the same rate.
- Trial name
- PlasMA (NCT06822283)
- Testing
- transcranial electric stimulation
- Where
- 2 sites in Switzerland
- Volunteers
- 19 people
- Sponsor
- Friedhelm Hummel
Alzheimer Disease
Deep Brain Stimulation in Alzheimer's Disease: Biomarkers and Dose Optimization
Title: Deep Brain Stimulation of the Fornix in Alzheimer's Disease: Investigating clinical and imaging biomarkers and dose optimization Objective: To evaluate the influence of deep brain stimulation in Alzheimer's Disease (AD)on…
- Trial name
- NCT04856072
- Testing
- Deep Brain Stimulation
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- University Health Network, Toronto